China SXT Pharmaceuticals, Inc.
SXTCNasdaq
$2.45
↓ -4.7%Jul 17 close · end-of-day
Price
1Y↓ -99.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.7M
Enterprise Value
-$25.5M
P/E
—
P/S
1.5
P/B
0.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$1.1M
Net Income (TTM)
-$6.2M
Free Cash Flow (TTM)
—
Gross Margin
21.9%
Operating Margin
-625.9%
Net Margin
-545.2%
ROE
-20.9%
ROIC
-222.3%
Debt / Equity
0.0
Net Cash
$27.2M
Return 1Y
-99.0%
Company profile
China SXT Pharmaceuticals, Inc. engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) The company provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company was founded in 2005 and is based in Taizhou, China.
- CEO
- Feng Zhou
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Website
- sxtchina.com
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | $4.8M | $2.6M | $2.0M | $1.9M | $1.7M | $1.1M |
| Gross profit | $2.8M | $1.3M | $426,271.00 | $553,971.00 | $367,427.00 | $248,702.00 |
| Operating income | -$2.2M | -$5.2M | -$5.6M | -$2.5M | -$2.7M | -$7.1M |
| Net income | -$2.7M | -$5.7M | -$5.9M | -$3.1M | -$3.3M | -$6.2M |
| Diluted EPS | -$3.82 | -$137.92 | -$177.84 | -$4,285.66 | -$348.17 | -$9.13 |
| Operating cash flow | -$1.3M | $268,293.00 | -$80,757.00 | -$1.9M | -$2.3M | -$4.0M |
| Free cash flow | — | — | — | -$1.9M | -$2.3M | — |
| Gross margin | 59.4% | 48.1% | 21.6% | 28.7% | 21.1% | 21.9% |
| Operating margin | -46.0% | -199.4% | -284.4% | -130.4% | -154.0% | -625.9% |
| Net margin | -57.5% | -220.4% | -301.0% | -160.7% | -189.8% | -545.2% |
No quarterly data.
Company news
Mar 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.